Phase 3 Hormone Clinical Trials
15 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.206 enrolled1 locationNCT07241416
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled158 locationsNCT06982521
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled536 locationsNCT06058377
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled300 locationsNCT07028853
Recruiting
Phase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Growth Hormone Deficiency (GHD)
Lumos Pharma150 enrolled28 locationsNCT06948214
Recruiting
Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
Mild Traumatic Brain InjuryAdult Growth Hormone Deficiency
VA Office of Research and Development172 enrolled4 locationsNCT04867317
Recruiting
Phase 3
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Hypothalamic ObesityMultiple Pituitary Hormone Deficiency Genetic FormSepto-Optic Dysplasia+3 more
Rhythm Pharmaceuticals, Inc.39 enrolled11 locationsNCT06760546
Recruiting
Phase 3
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Phase 3
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
Preimplantation Genetic TestingGrowth HormoneAge, Parental
ShangHai Ji Ai Genetics & IVF Institute400 enrolled1 locationNCT05447208
Recruiting
Phase 3
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783
Recruiting
Phase 3
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05956639
Recruiting
Phase 3
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University1,736 enrolled1 locationNCT05901428
Not Yet Recruiting
Phase 3Phase 4
Detection of gonadotropin releasing hormone (GnRH) analogs as doping or masking agents
Detection of gonadotropin relaeasing hormone (GnRH) analogs in healthy males, as a sports doping agent.
Sydney South Western Area Health Service (SSWAHS)32 enrolled1 locationACTRN12609000189224
Completed
Phase 3
SWOG 0230 / IBCSG 34-05
Ovarian function in premenopasual women with early stage, hormone-receptor negative breast cancer
Australia and New Zealand Breast Cancer Trials Group416 enrolled1 locationACTRN12606000075583